The primary objective of this project is to examine the impact of a strength training program with high cognitive demands on cognitive function, motor skills, physical fitness, and quality of life in individuals with Alzheimer's disease and mild cognitive impairment. This randomized controlled trial will involve participants for a total of five months. Initial two weeks will be for cognitive, physical fitness, quality of life, and specific biochemical profile evaluations, along with familiarization sessions with the exercise routine. The experimental group will then undertake a supervised strength training program twice a week for 16 weeks. The final two weeks will involve re-evaluations of all initial assessments. Participants will be randomized into a control group and an intervention group with a minimum of 17 individuals each. Stratification criteria for randomization include physical activity level, number of Alzheimer's disease-related risk factors, extent of brain damage based on MRI biomarkers, and clinical dementia rating scores.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Global cognitive performance
Timeframe: Baseline (pre-intervention, week 0) and immediately after intervention (week 16).
Clinical Assessment of Dementia
Timeframe: Baseline (week 0) and immediately after the 12-week intervention (week 16)
Isometric knee flexion-extension strength
Timeframe: Baseline (week 0) and immediately after the 12-week intervention (week 16)
Number of repetitions in the 30-second Sit-to-Stand test
Timeframe: Baseline (week 0) and immediately after the 12-week intervention (week 16)
Handgrip strength
Timeframe: Baseline (week 0) and immediately after the 12-week intervention (week 16)
10m walking velocity
Timeframe: Baseline (week 0) and immediately after the 12-week intervention (week 16)
Time to complete the Timed Up and Go test (3 meters)
Timeframe: Baseline (week 0) and immediately after the 12-week intervention (week 16)
Decrement in walking speed during dual-task 10m walk test
Timeframe: Baseline (week 0) and immediately after the 12-week intervention (week 16)
Health-related quality of life measured by EuroQol-5D (EQ-5D)
Timeframe: Baseline (week 0) and immediately after the 12-week intervention (week 16)
Distance walked in the 6-Minute Walk Test (6MWT)
Timeframe: Baseline (week 0) and immediately after the 12-week intervention (week 16)